ABSTRACT
BACKGROUND: We sought to investigate the effect of obesity and BMI on functional outcome and rate of symptomatic intracranial hemorrhage (sICH) in a large sample of patients with acute ischemic stroke (AIS) treated with intravenous thrombolysis (IVT). METHODS: In a single-center retrospective, but prospectively collected data, study of patients with AIS treated with IVT in a 10-year period, patients were placed into groups based on their BMI defined as underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), or obese (<30 kg/m2). The rate of sICH and discharge modified Rankin Scale (mRS) were compared between the groups using logistic regression analysis. RESULTS: In a total of 834 patients who received IVT for AIS during a 10-year period, 224 (27.0%) were obese. Obese patients did not have a higher rate of sICH after IVT for AIS on the unadjusted or adjusted analysis (adjusted OR 0.95, 95% CI 0.48-1.88). We did not find an association between obesity and poor functional outcome at discharge (adjusted OR 0.76, 95% CI 0.53-1.09). CONCLUSIONS: After adjusting for confounding factors such as age, baseline National Institute of Health Stroke Scale (NIHSS), and comorbidities, obesity was not associated with an unfavorable functional outcome at discharge nor with a higher risk of sICH in patients with AIS treated with IVT.
Subject(s)
Body Mass Index , Fibrinolytic Agents/administration & dosage , Obesity/complications , Thrombolytic Therapy , Aged , Aged, 80 and over , Female , Fibrinolytic Agents/adverse effects , Humans , Infusions, Intravenous , Intracranial Hemorrhages/chemically induced , Ischemic Stroke/complications , Ischemic Stroke/diagnosis , Ischemic Stroke/drug therapy , Male , Middle Aged , Obesity/diagnosis , Retrospective Studies , Risk Assessment , Risk Factors , Thrombolytic Therapy/adverse effects , Treatment OutcomeABSTRACT
AIM: The aim of this was to study the effects of statins and their intensity on symptomatic intracranial hemorrhage (sICH) and outcome after IV thrombolysis (IVT) for acute ischemic stroke (AIS). METHODS: We retrospectively reviewed the medical records and cerebrovascular images of all the patients treated with IVT for AIS in our center in a 10-year period. Patients were further characterized as any statin users versus non-users on admission to the emergency department. Statins were categorized in high intensity or low intensity statin based on its propensity to reduce lower low-density cholesterol by ≥45% or <45%, respectively. Safety and discharge modified Rankin Score were compared between statin users versus non-users and also between high-intensity versus low-intensity groups. RESULTS: A total of 834 patients received IVT for AIS in our center during a 10-year period. Multivariate models were adjusted for age, NIH Stroke Scale at admission, INR, and history of DM and atrial fibrillation. There was no association between odds of sICH and any statin use (OR = 0.52 [0.26-1.03], p = 0.06). In multivariate model, any statin use was not associated with odds of poor outcome (Table 4: OR = 1.01 [0.79-1.55], p = 0.57). There was no significant association between odds of sICH among patients on high-intensity statin compared to low intensity statin (multivariate model OR = 0.39 [0.11-1.40], p = 0.15). There was 47% reduced odds of poor outcome among patients on high-intensity statin as compared to low-intensity statin (OR = 0.53[0.32-0.88] p = 0.01). However, this significant association was lost in the multivariate model (OR = 0.60 [0.35-1.05], p = 0.07). CONCLUSION: Our study does not show any significant association between risk of sICH and poor outcome after IVT for patients on prior statin therapy. We also did not find significant association between the risk of sICH and poor outcome after IVT and the intensity of the stain used.
Subject(s)
Brain Ischemia/drug therapy , Dyslipidemias/drug therapy , Fibrinolytic Agents/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Stroke/drug therapy , Thrombolytic Therapy , Administration, Intravenous , Aged , Aged, 80 and over , Brain Ischemia/diagnosis , Dyslipidemias/diagnosis , Female , Fibrinolytic Agents/adverse effects , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Intracranial Hemorrhages/chemically induced , Male , Middle Aged , Retrospective Studies , Risk Assessment , Risk Factors , Stroke/diagnosis , Thrombolytic Therapy/adverse effects , Time Factors , Treatment OutcomeABSTRACT
Burning mouth syndrome affects 1-3% of the population The exact mechanism is unknown. Bartoshuk has demonstrated sweet hypogeusia in those with burning mouth syndrome. Intensification of sweet taste may compensate for this deficit and reduce the pain.
